Figure 1From: Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies Survival of patients treated with the R-2-CdA regimen (n = 13). Kaplan-Meier overall survival from end of therapy with R-2-CdA to last follow up (censored) or death. Median survival is 7.9 years.Back to article page